BMC veterinary research · 2026
Glycyrrhiza polysaccharide inhibits feline infectious peritonitis virus infection screened by a recombinant virus expressing eGFP protein.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yang Yuan, Fu Haixia, Chang Mengyu, Zhang Mengjia, Zhou Jiaru, Xu Kangkai, Yang Mingjun, Li Wentao, Zhu Hongmei
Аннотация
BACKGROUND: Feline infectious peritonitis (FIP) is a fatal infectious disease caused by feline infectious peritonitis virus (FIPV) which causes death of young cats less than 2 years old. Until now, few drugs are available for treatment of FIP. Here, we developed a modified FIPV expressing eGFP reporter gene by reverse genetics to evaluate the ability of Chinese herbal polysaccharides on inhibition of FIPV infection in Crandell-Rees feline kidney (CRFK) cells.
RESULTS: The results demonstrated that the recombinant FIPV could express eGFP reporter gene, replicated in the CRFK cells and grow in a similar way with wild-type FIPV. By using this recombinant FIPV, we found that glycyrrhiza polysaccharide (GPS) effectively inhibited FIPV when added at the same time with virus or post-infection in CRFK cells. Further studies revealed that GPS inhibited FIPV adsorption and replication, but did not affect FIPV internalization in CRFK cells.
CONCLUSIONS: In the current study, we successfully established a modified FIPV platform which supports high-throughput drug screening in vitro, and we found that GPS is a promising candidate for treating FIP.
RESULTS: The results demonstrated that the recombinant FIPV could express eGFP reporter gene, replicated in the CRFK cells and grow in a similar way with wild-type FIPV. By using this recombinant FIPV, we found that glycyrrhiza polysaccharide (GPS) effectively inhibited FIPV when added at the same time with virus or post-infection in CRFK cells. Further studies revealed that GPS inhibited FIPV adsorption and replication, but did not affect FIPV internalization in CRFK cells.
CONCLUSIONS: In the current study, we successfully established a modified FIPV platform which supports high-throughput drug screening in vitro, and we found that GPS is a promising candidate for treating FIP.